Psychedelics Could Help People Quit Smoking
Last reviewed and updated: August 17, 2026.
Key Takeaways
| The finding | A Johns Hopkins pilot study found psilocybin-assisted therapy helped a high share of smokers quit, far above standard treatments. |
| The numbers | In the pilot, 80 percent were abstinent at 6 months and about 60 to 67 percent at 12 months, though the study was small. |
| The big caveat | The study had only 15 participants and no control group, so the striking results are promising but preliminary. |
| Being tested further | A larger randomized controlled trial comparing psilocybin with nicotine replacement has been underway to confirm the effect. |
| Not approved | Psilocybin for smoking cessation remains investigational and is not FDA-approved as of 2026. |
A new study has provided some hope for anyone who’s tried (and failed) to quit cigarettes. And surprisingly, it looks like psychedelics could be the one option to help people quit smoking.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
The Role of Psychedelics
Psychedelics, such as psilocybin, have garnered attention for their potential in treating various addictions. A systematic review published in Discover Mental Health examined the efficacy of psychedelics in addressing tobacco use disorder. The review analyzed studies up to March 2024, identifying eight pertinent publications. Notably, seven of these focused on psilocybin, suggesting its promise in aiding smoking cessation.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Breakdown of the Smoking Cessation Study
| Parameter | Details |
|---|---|
| Study Type | Clinical trial |
| Participants | 15 mentally healthy smokers |
| Psychedelic Substance | Psilocybin |
| Therapeutic Approach | Combination of psilocybin sessions and cognitive-behavioral therapy (CBT) |
| Main Outcome | Smoking cessation |
| Success Rate at 6 Months | 80% (12 out of 15 participants achieved abstinence) |
| Comparison to Conventional Methods | Significantly higher success rate compared to traditional cessation therapies (<25% one-year success rate) |
| Mechanism of Action | Interaction with 5-HT2A serotonin receptors leading to altered states of consciousness and insights |
| Follow-Up Duration | 6 months |
| Study Limitations | Small sample size, limited diversity of participants, short follow-up period |
Clinical Insights
One significant study involved 15 mentally healthy smokers who underwent psilocybin sessions combined with cognitive-behavioral therapy. The results were compelling: 80% of participants achieved abstinence at the six-month follow-up. This outcome contrasts sharply with the modest success rates of conventional therapies.
Read more on this story at Marijuana Moment.
Mechanisms at Play
What makes psychedelics effective in this context? Research indicates that substances like psilocybin interact with serotonin receptors, particularly the 5-HT2A receptor, leading to altered states of consciousness. These experiences may facilitate profound personal insights and behavioral changes, potentially reducing the compulsion to smoke.
Broader Implications
Beyond psilocybin, other psychedelics, including ayahuasca, mescaline, peyote, LSD, LSA, and DMT, have been explored for smoking cessation. However, the evidence remains insufficient to draw definitive conclusions about their effectiveness.
Looking Ahead
While the findings are promising, they also prompt reflection. Could psychedelics redefine our approach to addiction treatment? What ethical and safety considerations should guide their integration into mainstream therapy? As research progresses, these questions will be central to the discourse on psychedelics in medicine.
Psilocybin for Quitting Smoking: What the Evidence Really Shows
The main evidence is a Johns Hopkins pilot study from 2014 of psilocybin-assisted therapy for smoking cessation. In it, 80 percent of participants were biologically confirmed abstinent at 6 months. Roughly 60 to 67 percent stayed abstinent at 12 months and beyond. These rates are far higher than standard smoking-cessation treatments, and the study drew wide attention as a result.
The pilot had only 15 participants and no control group, so the results, while striking, are preliminary. Open-label studies cannot rule out expectation and selection effects. Small samples can also overstate an effect. The finding is very promising, but it is not proof.
A larger randomized controlled trial comparing psilocybin with nicotine replacement has been underway to test whether the effect holds up under rigorous conditions. As of 2026, psilocybin for smoking cessation remains investigational and is not FDA-approved. Readers should treat it as a promising research direction rather than an available treatment.
Frequently Asked Questions
- Can psilocybin help you quit smoking?
- Early research suggests it might. A small Johns Hopkins pilot study found that 80 percent of participants were abstinent from smoking at 6 months after psilocybin-assisted therapy, far above standard treatments. However, the study had only 15 participants and no control group, so the results are promising but preliminary, and psilocybin is not an approved smoking treatment.
- How strong is the evidence that psilocybin helps smokers quit?
- The headline numbers are striking but the evidence is early. The main study was a small, open-label pilot of 15 people with no control group, which limits how much can be concluded. A larger randomized controlled trial has been underway to test whether the effect holds. Until that data is in, the finding should be treated as promising rather than proven.
- Why might psilocybin help with quitting smoking?
- Researchers think psilocybin may help people break entrenched habits by increasing psychological flexibility and motivation, and by making the decision to quit feel more meaningful. Paired with therapy, the experience may weaken the automatic patterns behind addiction. This is a leading hypothesis, though the exact mechanism is still being studied.
- Is psilocybin an approved treatment for smoking?
- No. Psilocybin remains a Schedule I substance and is not FDA-approved for smoking cessation or any other condition. The research is promising, especially the Johns Hopkins pilot, but larger controlled trials are needed. For now, psilocybin for quitting smoking is investigational and available only through research settings.
